Format

Send to

Choose Destination
Int J Cardiol Heart Vasc. 2019 Mar 28;23:100349. doi: 10.1016/j.ijcha.2019.100349. eCollection 2019 Jun.

The use of a single chamber leadless pacemaker for the treatment of cardioinhibitory vasovagal syncope.

Author information

1
University Hospital Southampton NHS Foundation Trust, United Kingdom.
2
The Leeds Teaching Hospitals NHS Trust, United Kingdom.
3
Guy's and St Thomas' NHS Foundation Trust, United Kingdom.
4
The James Cook University Hospital, Middlesborough, United Kingdom.
5
University Hospitals of Leicester NHS Trust, United Kingdom.
6
Blackpool Teaching Hospitals NHS Foundation Trust, United Kingdom.
7
Basildon and Thurrock University Hospitals NHS Foundation Trust, United Kingdom.
8
Liverpool Heart and Chest Hospital NHS Foundation Trust, United Kingdom.
9
Northampton General Hospital NHS Trust, United Kingdom.
10
The Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom.
11
West Hertfordshire Hospitals NHS Trust, United Kingdom.
12
Barts Health NHS Trust, United Kingdom.
13
Manchester University NHS Foundation Trust, United Kingdom.

Abstract

Background:

The use of pacemakers in the treatment of cardioinhibitory vasovagal syncope is controversial with a mixed message from the limited evidence base. Single chamber leadless pacemakers have been shown to be an effective alternative option to conventional pacemakers.

Objective:

This study examines the use of leadless pacemakers in a cardioinhibitory vasovagal population in the United Kingdom.

Methods:

Observational data on 32 patients implanted with the Micra Transcatheter Pacemaker System for vasovagal syncope are presented. Data was collected on implant indications, implant procedure and follow up data from 12 centres across the United Kingdom that had elected to use a Micra leadless pacemaker in this patient population.

Results:

32 patients aged 37 ± 14 years (range 18 to 64 years) with 62% of the patients being female were recruited to the study. Vasovagal syncope was diagnosed clinically and with the support of Holter monitoring, tilt table testing and implantable loop recorders. The duration of symptoms was 8 ± 8 yrs. with an average frequency of syncope being 4 ± 6 times/year. The Micra pacemaker was successfully implanted in all patients with a major complication rate of 3.1%. Patients were followed up for 404 ± 237 days (range 63-928 days). At follow up 28 (87%) patients were free from symptoms.

Conclusions:

This observational study suggests that the use of a single chamber leadless pacemaker in the treatment of cardioinhibitory vasovagal syncope might be a reasonable clinical option.

KEYWORDS:

Cardioinhibitory; Leadless pacemaker; Micra; Pacemaker; Syncope; Vasovagal

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center